Skip to content

Clinical trial of PROTECT-C hand sanitizer in SARS-CoV-2 infected subjects.

A prospective open label clinical trial to evaluate the topical viral load reduction potential of PROTECT-C hand sanitizer on SARS-CoV-2 infected subjects. - Nil

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/034624
Enrollment
100
Registered
2021-07-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: PROTECT C Hand sanitizer spray Stabilized chlorine dioxide solution: Spray appropriate amount of PROTECT C hand sanitizer solution on palm, rub hands together, covering entire hand, inc

Sponsors

MIYAKAWA KOGYO INDIA PVT LTD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Tested SARS- CoV-2 positive within last 8 days of study enrolment. Patients willing to sign written informed consent and are ready to comply to study procedure. SARS-CoV-2 positive asymptomatic or symptomatic patients who are under institutional quarantine/ home isolated/ hospitalized.

Exclusion criteria

Exclusion criteria: Patients on ventilator support. Pregnant or lactating woman. Subjects with history of sun burn on hands. Subjects with history of skin disorders or on medication for the same: Eczema, Urticaria, Psoriasis, Herpes, skin cancer, Lupus, Vitiligo, Fungal infection, Candidiasis. Subjects on treatment of any degree burns. Any kind of psychiatric disorder or a condition in the opinion of the investigator may hinder communication with the research team. Inability of the subject to cooperate or communicate with the research team and provide follow up.

Design outcomes

Primary

MeasureTime frame
Clinically significant Quantitative Reduction of 80% Virus load from baseline to EOT.Timepoint: 90 sec

Secondary

MeasureTime frame
Tolerability and safety of interventionTimepoint: 90 sec

Countries

India

Contacts

Public ContactMR SWAPNIL DIGHE

MIYAKAWA KOGYO INDIA PVT LTD

inquiry@miyakawa.co.in8888815766

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026